Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVEO AVEO Pharmaceuticals	$15.00	$14.97	$3.06 ▼ $15.00	$521.45M	1	601,442 shs	247,800 shs
CBIO Crescent Biopharma	$13.34 +2.5%	$0.00	$11.06 ▼ $63.00	$260.80M	1.52	34,486 shs	120,148 shs
ONCY Oncolytics Biotech	$1.27 -3.8%	$0.66	$0.33 ▼ $1.53	$119.74M	1.07	739,146 shs	1.19 million shs
ORMP Oramed Pharmaceuticals	$2.12	$2.18	$1.82 ▼ $3.09	$86.60M	1.59	140,463 shs	17,525 shs
SESN Sesen Bio		$10.50	$0.37 ▼ $12.58	$2.56B	0.83	1.07 million shs	93,330 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVEO AVEO Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
CBIO Crescent Biopharma	-0.91%	-3.56%	-17.57%	-98.30%	-98.30%
ONCY Oncolytics Biotech	+5.60%	+18.39%	+97.58%	+135.29%	+24.54%
ORMP Oramed Pharmaceuticals	+0.47%	0.00%	-1.85%	-1.40%	-17.51%
SESN Sesen Bio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CBIO Crescent Biopharma	3.2136 of 5 stars	3.8	0.0	0.0	3.7	2.7	1.7	0.6
ONCY Oncolytics Biotech	1.5061 of 5 stars	3.4	3.0	0.0	0.0	1.5	0.0	0.0
ORMP Oramed Pharmaceuticals	1.2268 of 5 stars	0.0	4.0	0.0	0.0	3.3	0.8	0.6
SESN Sesen Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVEO AVEO Pharmaceuticals	0.00	N/A	N/A	N/A
CBIO Crescent Biopharma	3.50	Strong Buy	$25.67	92.40% Upside
ONCY Oncolytics Biotech	2.75	Moderate Buy	$4.33	241.21% Upside
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A
SESN Sesen Bio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ONCY, AVEO, ORMP, CBIO, and SESN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$27.00
6/25/2025	CBIO Crescent Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$28.00
6/20/2025	CBIO Crescent Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/18/2025	CBIO Crescent Biopharma	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$22.00
5/21/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/16/2025	ONCY Oncolytics Biotech	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVEO AVEO Pharmaceuticals	$42.29M	12.33	N/A	N/A	$1.33 per share	11.28
CBIO Crescent Biopharma	$10K	26,079.70	N/A	N/A	$8.24 per share	1.62
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.05 per share	N/A
ORMP Oramed Pharmaceuticals	$1.34M	64.63	N/A	N/A	$3.61 per share	0.59
SESN Sesen Bio	$40M	0.00	N/A	3.39	$0.78 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVEO AVEO Pharmaceuticals	-$53.34M	-$0.84	N/A	28.85	N/A	-30.79%	-81.66%	-28.83%	N/A
CBIO Crescent Biopharma	-$37.88M	-$46.00	N/A	N/A	N/A	N/A	-293.92%	-206.20%	N/A
ONCY Oncolytics Biotech	-$23.14M	-$0.29	N/A	N/A	N/A	N/A	-313.77%	-130.19%	7/30/2025 (Estimated)
ORMP Oramed Pharmaceuticals	-$19.06M	-$0.44	N/A	N/A	N/A	N/A	-11.34%	-10.73%	8/13/2025 (Estimated)
SESN Sesen Bio	-$19.88M	-$0.10	N/A	N/A	N/A	N/A	6.70%	5.41%	N/A

Latest ONCY, AVEO, ORMP, CBIO, and SESN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	ORMP Oramed Pharmaceuticals	-$0.01	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ONCY Oncolytics Biotech	-$0.10	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	ORMP Oramed Pharmaceuticals	-$0.03	-$0.19	-$0.16	-$0.19	N/A	$2.00 million
5/14/2025	Q1 2025	ONCY Oncolytics Biotech	-$0.09	-$0.06	+$0.03	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SESN Sesen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVEO AVEO Pharmaceuticals	0.94	2.37	2.35
CBIO Crescent Biopharma	N/A	2.29	2.29
ONCY Oncolytics Biotech	N/A	3.20	3.20
ORMP Oramed Pharmaceuticals	N/A	23.94	23.94
SESN Sesen Bio	N/A	6.10	6.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVEO AVEO Pharmaceuticals	49.95%
CBIO Crescent Biopharma	75.19%
ONCY Oncolytics Biotech	6.82%
ORMP Oramed Pharmaceuticals	12.73%
SESN Sesen Bio	16.45%

Insider Ownership

Company	Insider Ownership
AVEO AVEO Pharmaceuticals	3.29%
CBIO Crescent Biopharma	4.00%
ONCY Oncolytics Biotech	0.10%
ORMP Oramed Pharmaceuticals	13.70%
SESN Sesen Bio	3.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVEO AVEO Pharmaceuticals	114	34.76 million	33.62 million	Optionable
CBIO Crescent Biopharma	50	19.55 million	18.77 million	No Data
ONCY Oncolytics Biotech	30	94.28 million	94.19 million	Not Optionable
ORMP Oramed Pharmaceuticals	10	40.85 million	35.25 million	Optionable
SESN Sesen Bio	35	203.49 million	196.98 million	Optionable

ONCY, AVEO, ORMP, CBIO, and SESN Headlines

Recent News About These Companies

Trey Mewes

April 9, 2024 | startribune.comS

Devin Haney: biography, record, fights and more

December 9, 2023 | espn.com

Tyson Fury: Biography, record, fights and more

December 2, 2023 | espn.com

Why the Tucker Carlson Biography Sales Are So Pathetic

September 13, 2023 | thedailybeast.comT

Sesen Bio (NASDAQ: SESN)

August 4, 2023 | fool.com

James McTeigue Biography & Movies

May 10, 2023 | tribute.caT

After revisions, Philadelphia-based Carisma Therapeutics poised to close merger with Sesen Bio

March 6, 2023 | bizjournals.com

Sesen Bio wins shareholder approval for Carisma merger

March 2, 2023 | msn.com

Sesen Bio Stockholders Approve Merger with Carisma Therapeutics

March 2, 2023 | finance.yahoo.com

Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results

February 28, 2023 | finance.yahoo.com

SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing Investigations

February 24, 2023 | benzinga.com

Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With Carisma

February 21, 2023 | finance.yahoo.com

BML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics

February 17, 2023 | stockhouse.com

Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting

February 16, 2023 | businesswire.com

Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger

February 16, 2023 | finance.yahoo.com

Sesen Bio reaches deal with investor group, paving way for Carisma merger

February 15, 2023 | endpts.comE

Latest terms of Sesen Bio and Carisma merger appear to pass muster

February 15, 2023 | thepharmaletter.comT

5 big dividend moves: Group 1 Automotive hikes by 20% | Pro Recap

February 15, 2023 | finance.yahoo.com

BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics

February 15, 2023 | finance.yahoo.com

Sesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor group

February 14, 2023 | bizjournals.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, AVEO, ORMP, CBIO, and SESN Company Descriptions

AVEO Pharmaceuticals NASDAQ:AVEO

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Crescent Biopharma NASDAQ:CBIO

$13.34 +0.32 (+2.46%)

As of 04:00 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Oncolytics Biotech NASDAQ:ONCY

$1.27 -0.05 (-3.79%)

Closing price 04:00 PM Eastern

Extended Trading

$1.27 +0.00 (+0.39%)

As of 07:53 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Oramed Pharmaceuticals NASDAQ:ORMP

$2.12 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.12 +0.00 (+0.24%)

As of 05:52 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Sesen Bio NASDAQ:SESN

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time